drugset / Trial / NCT05927844
XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.
Timeline
- Start
- 2023-06
- Primary completion
- 2025-06
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 30 mg | — |
| Subject | XH-30002 | Unknown | 300 mg | — |
| Subject | XH-30002 | Unknown | 400 mg | — |